Adoptive cell therapy with the use of tumor-infiltrating lymphocytes (TILs) is a very promising
immunotherapeutic approach for the treatment of patients with colorectal cancer (CRC) …

Background Microsatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1,
respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable …

Background Current stratification systems for tumor prognostic prediction and
immunotherapeutic efficacy evaluation are less satisfying in colorectal cancer (CRC). As …

Background Colorectal adenocarcinoma is the third most common cancer worldwide and a
leading cause of cancer-related death. The recent emergence of diverse immunotherapeutic …

The tumour microenvironment is an important factor for colorectal cancer prognosis,
affecting the patient's immune response. Immune checkpoints, which regulate the immune …

Background Cytotoxic CD8+ T cell-mediated response is the most important arm of adaptive
immunity, which dictates the capacity of the host immune response in eradicating tumor …

Despite recent advances in colorectal cancer (CRC) treatment, a large proportion of patients
show limited responses to therapies, especially in advanced stages. There is an urgent …

Increasing studies have highlighted the effects of the tumor immune micro-environment
(TIM) on colon cancer (CC) tumorigenesis, prognosis, and metastasis. However, there is no …

Immune checkpoint inhibitors (ICIs) have become a promising area of research for cancer
treatment. In addition to the well-known ICIs targeting PD-1/PD-L1, HLA-G/ILT-2/-4 is …

Anti-tumor immunity is a new line of research for the treatment of patients with solid tumors.
In this field, negative regulators of the immune system called immune checkpoints play a key …